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BACKGROUND
The order and magnitude of pathologic processes in Alzheimer’s disease are not well 
understood, partly because the disease develops over many years. Autosomal domi-
nant Alzheimer’s disease has a predictable age at onset and provides an opportunity 
to determine the sequence and magnitude of pathologic changes that culminate in 
symptomatic disease.
METHODS
In this prospective, longitudinal study, we analyzed data from 128 participants who 
underwent baseline clinical and cognitive assessments, brain imaging, and cerebro-
spinal fluid (CSF) and blood tests. We used the participant’s age at baseline assess-
ment and the parent’s age at the onset of symptoms of Alzheimer’s disease to calcu-
late the estimated years from expected symptom onset (age of the participant minus 
parent’s age at symptom onset). We conducted cross-sectional analyses of baseline 
data in relation to estimated years from expected symptom onset in order to deter-
mine the relative order and magnitude of pathophysiological changes.
RESULTS
Concentrations of amyloid-beta (Aβ)42 in the CSF appeared to decline 25 years before 
expected symptom onset. Aβ deposition, as measured by positron-emission tomog-
raphy with the use of Pittsburgh compound B, was detected 15 years before expected 
symptom onset. Increased concentrations of tau protein in the CSF and an increase 
in brain atrophy were detected 15 years before expected symptom onset. Cerebral 
hypometabolism and impaired episodic memory were observed 10 years before ex-
pected symptom onset. Global cognitive impairment, as measured by the Mini–Mental 
State Examination and the Clinical Dementia Rating scale, was detected 5 years be-
fore expected symptom onset, and patients met diagnostic criteria for dementia at 
an average of 3 years after expected symptom onset.
CONCLUSIONS
We found that autosomal dominant Alzheimer’s disease was associated with a se-
ries of pathophysiological changes over decades in CSF biochemical markers of 
Alzheimer’s disease, brain amyloid deposition, and brain metabolism as well as 
progressive cognitive impairment. Our results require confirmation with the use of 
longitudinal data and may not apply to patients with sporadic Alzheimer’s disease. 
(Funded by the National Institute on Aging and others; DIAN ClinicalTrials.gov 
number, NCT00869817.)
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A lzheimer’s disease is the most com-mon cause of dementia and is currently estimated to affect more than 5 million 
people in the United States, with an expected in-
crease to 13 million by the year 2050. The typical 
clinical presentation is progressive loss of mem-
ory and cognitive function, ultimately leading to 
a loss of independence and causing a heavy per-
sonal toll on the patient and the family. The costs 
of care of patients with Alzheimer’s disease in 
2010 were estimated at more than $172 billion in 
the United States, an annual cost that is predict-
ed to increase to a trillion dollars by 2050 unless 
disease-modifying treatments are developed.1
Alzheimer’s disease has been hypothesized to 
begin decades before the first symptoms mani-
fest.2-4 Thus, longitudinal studies of Alzheimer’s 
disease biomarkers take many years to show the 
full pathologic cascade of events that lead to de-
mentia. Furthermore, trials of disease-modifying 
treatment require large numbers of patients over 
extended periods owing to the slow progression of 
cognitive symptoms.5,6 Therefore, well-validated 
biomarkers of Alzheimer’s disease processes are 
needed to improve the design of clinical trials, 
develop more effective therapeutics, and offer the 
opportunity for prevention trials.7
On the basis of the amyloid hypothesis,8 
amyloid-beta (Aβ) is currently the most common 
disease-modifying target. Recent research indi-
cates that the targeting of amyloidosis in familial 
amyloid polyneuropathy improves clinical out-
comes.9-11 However, the order and timing of amy-
loidosis and other Alz hei mer’s disease processes 
that lead to clinical dementia are not well under-
stood. We hypothesized that autosomal domi-
nant Alz hei mer’s disease and the more common 
late-onset Alz hei mer’s disease12 have similar 
pathophysiological features. Although autosomal 
dominant Alz hei mer’s disease accounts for a 
relatively small proportion (approximately 1%) of 
cases of Alz hei mer’s disease, increasing evidence13 
suggests that it overlaps with sporadic Alz hei mer’s 
disease. Mutations in one of three genes (APP, 
PSEN1, and PSEN2) have been identified that cause 
alterations in Aβ processing and lead to Alz hei-
mer’s disease with complete penetrance. The age at 
clinical onset of autosomal dominant Alz hei mer’s 
disease is similar between generations14 and is 
affected mostly by the mutation type and back-
ground family genetics.15 We compared a wide 
range of pathophysiological markers between mu-
tation carriers and noncarriers as a function of 
the parental age at onset in order to evaluate the 
cascade of events that lead to dementia. Clinical, 
cognitive, imaging, and biochemical measures 
were compared between mutation carriers and 
noncarriers in the first large international cohort 
of families with autosomal dominant Alz hei mer’s 
disease.
Methods
STUDY DESIGN
Participants at risk for carrying a mutation for 
autosomal dominant Alz hei mer’s disease were 
enrolled in the Dominantly Inherited Alzheimer 
Network (DIAN) study at 1 of 10 sites. Each par-
ticipant was a member of a pedigree with a known 
mutation for autosomal dominant Alz hei mer’s 
disease. DIAN participants are assessed at base-
line and in subsequent years with comprehensive 
clinical, cognitive, imaging, and biochemical as-
sessments. Data from all 128 participants who 
were enrolled and who had completed baseline 
assessments between January 26, 2009, and the 
first data-cutoff point (April 28, 2011) went through 
quality-control checks and were included in the 
analysis (see the Methods section in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org). All participants provided 
written informed consent or assent with proxy con-
sent. All study procedures were approved by the 
Washington University Human Research Protec-
tion Office and the local institutional review boards 
of the participating sites. All authors vouch for the 
accuracy of the data and the fidelity of the study to 
the protocol (available at NEJM.org).
CLINICAL ASSESSMENTS
Participants underwent clinical assessments of 
cognitive change with the use of the Clinical De-
mentia Rating (CDR)16 scale, with CDR 0 indicat-
ing normal cognitive function, CDR 0.5 very mild 
impairment, and CDR 1 mild impairment. The 
DIAN assessments ascertained family history of 
Alz hei mer’s disease and medical history, and par-
ticipants underwent a physical examination, in-
cluding a neurologic evaluation (see the study 
protocol). Clinicians who performed the assess-
ments were not aware of the mutation status of 
participants. The parental age at onset was deter-
mined by a semistructured interview in which 
family members were asked about the age of first 
progressive cognitive decline (Fig. S1 in the Sup-
plementary Appendix). Clinical feedback was 
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provided to participants if medically indicated. 
No other research data, including genetic status, 
were provided to research participants as part of 
the study.
NEUROPSYCHOLOGICAL TESTING
Participants underwent a comprehensive battery 
of neuropsychological tests, but results of only 
two tests are reported here because of space lim-
itations; both tests are widely used in research on 
Alz hei mer’s disease. The Mini–Mental State Ex-
amination (MMSE)17 is a measure of general cog-
nitive function, with scores ranging from 0 (se-
vere impairment) to 30 (no impairment). Story A 
from the Logical Memory subtest of the Wechsler 
Memory Scale–Revised18 is a measure of episodic 
memory. Participants recall as many details as they 
can from a short story containing 25 bits of infor-
mation after it is read aloud by the examiner and 
again after a 30-minute delay, with scores rang-
ing from 0 (no recall) to 25 (complete recall).
BRAIN IMAGING
Volumetric magnetic resonance imaging (MRI) 
was performed with the use of qualified 3-tesla 
scanners at each site; initial and ongoing quality 
control and matching between site scanners were 
performed according to the Alz hei mer’s Disease 
Neuroimaging Initiative (ADNI) protocol.19 All 
images were reviewed for image quality and com-
pliance with the acquisition protocol by the ADNI 
imaging core laboratories. The T1-weighted MRI 
scans from DIAN participants were processed 
through FreeSurfer (for details, see the Supplemen-
tary Appendix). Images obtained through positron-
emission tomography (PET) with the use of fluo-
rodeoxyglucose (FDG) and Pittsburgh compound B 
(PIB) (FDG-PET and PIB-PET, respectively) were 
then coregistered with individual MRI images 
for region-of-interest determination. For each 
FreeSurfer region of interest, the standardized 
uptake value ratio (SUVR) was calculated with 
the use of a hand-drawn reference region en-
compassing the brain stem. An increased PIB 
SUVR indicates increased binding to fibrillar 
amyloid, and a decreased FDG SUVR indicates 
decreased metabolism.
BIOCHEMICAL ANALYSIS
Cerebrospinal fluid (CSF) and blood were collect-
ed in the morning under fasting conditions by 
means of lumbar puncture and venipuncture, re-
spectively. Samples were shipped on dry ice to 
the DIAN biomarker core laboratory. Concentra-
tions in the CSF of Aβ1-42, total tau, and tau 
phosphorylated at threonine 181 were measured 
by immunoassay (INNOTEST β-Amyloid1-42 and 
INNO-BIA AlzBio3, Innogenetics), as were levels 
of plasma Aβ species (Aβ1-40, Aβ1-42, Aβx-40, and 
Aβx-42) (INNO-BIA Plasma Aβ Forms Multiplex 
Assay, Innogenetics). All values had to meet 
quality-control standards, including a coefficient 
of variation of 25% or less, kit “controls” within 
the expected range as defined by the manufac-
turer, and measurement consistency between 
plates of a common sample that was included in 
each run.
STATISTICAL ANALYSIS
The estimated years from expected symptom on-
set were calculated as the age of the participant 
at the time of the study assessment minus the 
age of the parent at symptom onset. For example, 
if the participant’s age was 35 years, and the par-
ent’s age at onset was 45 years, then the esti-
mated years from expected symptom onset would 
be −10. The parental age at the onset of clinical 
symptoms was determined by a semistructured 
interview with the use of all available historical 
data (Fig. S1 in the Supplementary Appendix). 
Clinical, cognitive, imaging, and biochemical 
measures were compared as a function of esti-
mated years from expected symptom onset be-
tween mutation carriers and noncarriers. Statis-
tical analyses (see the Supplementary Appendix 
for details) were conducted with the use of the 
PROC MIXED procedure in SAS software, version 
9.3 (SAS Institute). With each marker treated as a 
Table 1. Characteristics of the Study Participants.*
Characteristic
Carriers
(N = 88)
Noncarriers
(N = 40) P Value
Age — yr 39.1±10.3 39.5±8.9 0.92
Male sex — no. (%) 36 (41) 17 (42) 0.85
Education level — yr 13.9±2.5 15.0±2.5 0.04
Cognitive status — no. (%)†
Symptomatic 43 (49) 1 (2) 0.29
Asymptomatic 45 (51) 39 (98)
Positive for apolipoprotein E  
ε4 allele — no. (%)
22 (25) 9 (22) 0.69
* Plus–minus values are means ±SD.
† Participants were defined as asymptomatic if they had Cognitive Dementia 
Rating scores of 0 (no cognitive decline) and as symptomatic if they had 
scores greater than 0.
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continuous scale, a linear mixed model was used 
to model each marker as a function of estimated 
years from expected symptom onset, mutation 
status (carrier or noncarrier), and apolipoprotein 
E (APOE) status (positive or negative). Approxi-
mate Student’s t-test results derived from the 
model were used to determine whether marker 
values differed between mutation carriers and 
noncarriers at certain age points (Table S4 in the 
Supplementary Appendix), after adjustment for 
the correlation among family members. Values 
for individual participants were not displayed on 
graphs to protect the confidentiality of the mu-
tation status of participants (e.g., a participant 
who did not know his or her mutation status 
could deduce it from individual values of estimat-
ed years from expected symptom onset). Figure 2 
was generated with the same final models, with 
the use of the standardized difference between 
mutation carriers and noncarriers as a function 
of estimated years from expected symptom onset 
— that is, the predicted difference at each esti-
mated year from expected symptom onset divid-
ed by the standard deviation for clinical, cogni-
tive, imaging, and biochemical measures.
Results
STUDY PARTICIPANTS
We analyzed 128 participants from the DIAN co-
hort (Table 1). The mutation types reflected the dis-
tribution of mutations described in the literature, 
Table 2. Clinical, Cognitive, Imaging, and Biochemical Estimates in Mutation Carriers and Noncarriers.*
Variable Estimated Years from Expected Symptom Onset
−25 −20 −15 −10 −5 0 5 10
CDR-SOB score (no.)†
Noncarriers 0 0 0 0 0 0 0 0
Carriers 0 0 0.2 0.7 1.5 2.6 4.0 5.7
Difference 0±2.2 0±1.4 0.2±1.1 0.7±1.1 1.5±1.1‡ 2.6±1.1§ 4.0±1.3§ 5.7±1.7§
MMSE score (no.)¶
Noncarriers 29.4 29.5 29.5 29.5 29.6 29.6 29.6 29.7
Carriers 29.9 29.7 29.1 28.1 26.5 24.6 22.1 19.3
Difference 0.5±4.0 0.2±2.5 −0.4±1.9 −1.4±1.9 −3.1±2.0‡ −5.0±2.0§ −7.5±2.2§ −10.4±3.1§
Logical Memory score (no.)‖
Noncarriers 14.7 15.6 15.1 13.9 12.5 11.3 10.8 11.7
Carriers 16.3 15.9 14.1 11.4 8.3 5.2 2.8 1.4
Difference 1.6±4.2 0.3±2.7 −1.0±2.0 −2.5±2.0** −4.2±2.2§ −6.1±2.2§ −8.0±2.5§ −10.3±3.7§
Aβ deposition in the precuneus  
(SUVR ratio)††
Noncarriers 0.69 0.69 0.69 0.70 0.70 0.69 0.68 0.67
Carriers 0.71 0.76 0.9 1.08 1.24 1.36 1.38 1.24
Difference 0.02±0.28 0.07±0.17 0.21±0.15‡ 0.38±0.13§ 0.54±0.12§ 0.67±0.15§ 0.70±0.17§ 0.57±0.21§
Glucose metabolism in the precuneus 
(SUVR ratio)‡‡
Noncarriers 2.06 2.04 2.01 1.99 1.97 1.95 1.92 1.90
Carriers 2.16 2.05 1.94 1.83 1.72 1.61 1.50 1.39
Difference 0.10±0.16 0.01±0.13 −0.07±0.11 −0.16±0.09§ −0.25±0.08§ −0.34±0.09§ −0.42±0.12§ −0.51±0.15§
Total hippocampal volume (mm3)
Noncarriers 8999 8874 8748 8622 8497 8371 8245 8120
Carriers 8767 8511 8255 7999 7743 7486 7230 6974
Difference −232±675 −363±548 −493±442** −623±370‡ −754±356§ −885±406§ −1015±500§ −1146±619§
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with 40 PSEN1, 3 PSEN2, and 8 APP pedigrees.20 As 
expected with an autosomal dominant inheritance 
pattern, approximately 50% of the asymptomatic 
participants were mutation carriers. There were no 
significant differences in the presence of an APOE 
ε4 allele or sex between asymptomatic mutation 
carriers and noncarriers. The mean (±SD) age of 
parental onset of symptoms was 45.7±6.8 years. 
The DIAN parental age of symptom onset was cor-
related with the age of symptom onset for symp-
tomatic offspring (Pearson correlation coefficient, 
0.56; P<0.001).
CLINICAL and NEUROPSYCHOMETRIC FINDINGS
We measured clinical impairment with the use 
of the Clinical Dementia Rating–Sum of Boxes 
(CDR-SOB), with scores ranging from 0 (cognitive 
normality) to 18 (maximal cognitive impairment). 
Significant differences in CDR-SOB scores were 
detected between mutation carriers and noncarri-
ers 5 years before expected symptom onset (Fig. 1A 
and Table 2). Noncarriers had stable CDR-SOB 
scores of 0 throughout the relative age range, 
whereas carriers had increasing CDR-SOB scores 
at higher values of estimated years from expected 
symptom onset. In this cohort, participants had a 
CDR rating of mild dementia (CDR 1) at a mean 
of 3.3±5.3 years after the parent’s age of symp-
tom onset.
Significant differences in MMSE scores be-
tween mutation carriers and noncarriers were de-
tected at assessments performed 5 years before 
expected symptom onset; carriers had decreasing 
MMSE scores at higher values of estimated years 
from expected symptom onset (Fig. 1B). We found 
significant cognitive impairment in mutation car-
Table 2. (Continued.)
Variable Estimated Years from Expected Symptom Onset
−25 −20 −15 −10 −5 0 5 10
Aβ42 in the CSF (pg/ml)
Noncarriers 454 436 421 410 402 398 397 399
Carriers 532 433 352 289 245 218 210 219
Difference 78±149 −3±97 −69±82 −121±85‡ −157±88§ −180±90§ −187±107‡ −180±155**
Tau in the CSF (pg/ml)
Noncarriers 39 41 42 44 45 47 48 50
Carriers 35 55 76 97 117 138 159 179
Difference −4±52 14±41 34±33** 53±27§ 72±27§ 91±31§ 111±39§ 129±50§
Plasma Aβ42 (pg/ml)
Noncarriers 37.0 34.8 33.1 31.7 30.8 30.3 30.2 30.5
Carriers 42.4 41.8 41.6 41.9 42.5 43.5 45.0 46.9
Difference 5.4±10.8 7.0±8.7 8.5±7.0** 10.2±6.0‡ 11.7±5.8§ 13.2±6.8§ 14.8±8.5§ 16.4±10.5§
*  The timing of assessments was defined on the basis of the estimated years from expected symptom onset, calculated as the age of the 
participant at assessment minus the age of the parent at symptom onset. Estimates are reported with 95% confidence intervals for the 
difference between mutation carriers and noncarriers. Estimates were obtained with use of a mixed model that treated mutation status 
(noncarrier or carrier), estimated year from expected symptom onset (or higher-order term), and interactions between mutation status 
and estimated year from expected symptom onset as covariates regardless of the participant’s score on the Clinical Dementia Rating– 
Sum of Boxes (CDR-SOB) (Table S3 in the Supplementary Appendix). CSF denotes cerebrospinal fluid, and SUVR standardized uptake  
value ratio.
†  Scores on the CDR-SOB range from 0 (cognitive normality) to 18 (maximal cognitive impairment).
‡  P<0.01.
§  P<0.001.
¶  Scores on the Mini–Mental State Examination (MMSE) range from 0 (severe impairment) to 30 (no impairment). A score higher than 27 
is considered normal.
‖  Scores on the Logical Memory subtest of the Wechsler Memory Scale–Revised range from 0 (no recall) to 25 (complete recall).
** P<0.05.
†† Deposition of amyloid-beta (Aβ) in the precuneus was measured by positron-emission tomography (PET) with the use of Pittsburgh com-
pound B (PIB). A higher SUVR indicates greater binding of PIB to fibrillar amyloid.
‡‡ Glucose metabolism in the precuneus was measured by PET with the use of fluorodeoxyglucose. A lower SUVR indicates lower metabolism.
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riers, as compared with noncarriers, in the de-
layed-recall portion of the Logical Memory test21 
10 years before expected symptom onset (Table 2). 
Noncarriers remained stable in performance 
from 30 years before to 20 years after expected 
symptom onset (Fig. 1C).
BRAIN ATROPHY
MRI structural measures of hippocampal volume 
were compared between mutation carriers and 
noncarriers with the use of an a priori hypothesis 
of increased atrophy in mutation carriers. In-
creased atrophy of bilateral hippocampi was de-
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Figure 1. Cross-Sectional Analyses of Clinical, Cognitive, Structural, Metabolic, and Biochemical Changes in Autosomal Dominant 
Alzheimer’s Disease Mutation Carriers versus Noncarriers, According to Estimated Years from Expected Symptom Onset.
The clinical and cognitive measures of the Clinical Dementia Rating–Sum of Boxes (scores range from 0 [cognitive normality] to 18 [maximal 
cognitive impairment]) (Panel A), the Mini–Mental State Examination (scores range from 0 [severe impairment] to 30 [no impairment]) 
(Panel B), and the Logical Memory subtest of the Wechsler Memory Scale–Revised (scores range from 0 [no recall] to 25 [complete recall]) 
(Panel C) showed impaired ratings beginning approximately 5 to 10 years before expected symptom onset. MRI measures of hippocampal 
volume (Panel D) showed increased brain atrophy approximately 15 years before expected symptom onset. Decreases in cerebral glucose 
metabolism, as measured by positron-emission tomography (PET) with the use of fluorodeoxyglucose (Panel E), occurred approximately 
10 years before expected symptom onset, and deposition of amyloid-beta (Aβ) in the precuneus, as measured by PET with the use of Pitts-
burgh compound B (Panel F), began approximately 15 to 20 years before expected symptom onset. In the cerebrospinal fluid (CSF), levels 
of tau protein (Panel G) increased beginning 10 to 15 years before expected symptom onset, and levels of Aβ42 (Panel H) decreased at least 
15 years before expected symptom onset. Plasma Aβ42 levels were elevated throughout the range of estimated years from expected symptom 
onset (Panel I). Dashed lines represent 95% confidence intervals of the fitted curves. SUVR denotes standardized uptake value ratio.
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tected in mutation carriers 15 years before expect-
ed symptom onset (Table 2). As expected, there 
was an age-dependent decrease in hippocampal 
volumes in noncarriers (Fig. 1D).22
CEREBRAL GLUCOSE METABOLISM
FDG-PET measures of cerebral glucose use in the 
precuneus were compared with the use of an a 
priori hypothesis of decreased metabolism in 
mutation carriers to determine regional metabolic 
defects. The precuneus region, which is known 
to be an area of early deposition in both sporadic 
Alz hei mer’s disease and autosomal dominant Alz-
hei mer’s disease,4,23,24 was chosen for analysis of 
amyloid deposition. A significant decrease in cere-
bral metabolism in the precuneus was detected in 
mutation carriers 10 years before expected symp-
tom onset (Fig. 1E and Table 2).
Aβ DEPOSITION
PIB-PET measures of fibrillar Aβ deposition25 in 
the precuneus were compared with the use of an 
a priori hypothesis of increased regional amounts 
of amyloid deposition in mutation carriers. There 
was no detectable amyloid deposition in noncar-
riers. All noncarriers had PIB-PET SUVR values of 
less than 0.88. As compared with noncarriers, 
mutation carriers had significant amyloid deposi-
tion in the precuneus 15 years before expected 
symptom onset (Fig. 1F and Table 2). The amount 
of amyloid deposition in mutation carriers in-
creased as a function of estimated years from ex-
pected symptom onset at least until clinical symp-
tom onset.
BIOCHEMICAL MEASURES
In mutation carriers, levels of tau in the CSF were 
increased 15 years before expected symptom onset 
(Fig. 1G and Table 2). Concentrations of Aβ42 in 
the CSF decreased as a function of estimated years 
from expected symptom onset and were pseudo-
normal at approximately 20 years before expected 
symptom onset, reaching low levels 10 years be-
fore expected symptom onset (Fig. 1H). The de-
crease by half in Aβ42 in the CSF and the increase 
in tau in the CSF were similar in magnitude to 
those typically observed in late-onset sporadic Alz-
hei mer’s disease.26 Plasma Aβ42 levels were elevat-
ed in mutation carriers, as compared with non-
carriers (Fig. 1I).
COMBINED MODEL
The order and rate of pathophysiological changes 
in autosomal dominant Alz hei mer’s disease were 
estimated with the use of an analysis of the rela-
tionship among clinical, cognitive, imaging, and 
biochemical measures in the DIAN cohort (Fig. 2). 
Beginning 25 years before expected symptom on-
set, Aβ42 concentrations in the CSF in mutation 
carriers appeared to decline, as compared with 
those in noncarriers. Aβ deposition as measured 
by PIB-PET (Fig. 3; and see Video 1, available at 
NEJM.org) was detected at least 15 years before 
expected symptom onset (Table 2). Increases in 
levels of tau in the CSF and in brain atrophy were 
detected approximately 15 years before expected 
symptom onset, followed by cerebral hypometab-
olism and impaired episodic memory approximate-
ly 10 years before expected symptom onset and 
global cognitive impairment starting at 5 years 
before expected symptom onset.
A video showing 
Aβ deposition over 
time is available 
at NEJM.org
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Figure 2. Comparison of Clinical, Cognitive, Structural, Metabolic, and 
Biochemical Changes as a Function of Estimated Years from Expected 
Symptom Onset.
The normalized differences between mutation carriers and noncarriers are 
shown versus estimated years from expected symptom onset and plotted 
with a fitted curve. The order of differences suggests decreasing Aβ42 in 
the CSF (CSF Aβ42), followed by fibrillar Aβ deposition, then increased tau 
in the CSF (CSF tau), followed by hippocampal atrophy and hypometabo-
lism, with cognitive and clinical changes (as measured by the Clinical De-
mentia Rating–Sum of Boxes [CDR-SOB]) occurring later. Mild dementia 
(CDR 1) occurred an average of 3.3 years before expected symptom onset. 
95% confidence interval bands are shown in Figure S2 in the Supplementary 
Appendix.
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Discussion
Previous studies of autosomal dominant Alz hei-
mer’s disease have showed hippocampal atrophy,27 
fibrillar amyloidosis,28 and biochemical abnor-
malities in the CSF.29 With the establishment of 
DIAN, a worldwide network of autosomal domi-
nant Alz hei mer’s disease centers, we have estimat-
ed the timing and order of changes in autosomal 
dominant Alz hei mer’s disease in a large cohort 
with the disease. Changes begin in the brain at 
least two decades before the estimated onset of 
clinical symptoms. With the use of estimates of 
years from expected symptom onset, the order 
and magnitude of changes indicate that genetic 
mutations cause increased Aβ42, which is fol-
lowed by brain amyloidosis, tauopathy, brain at-
rophy, and decreased glucose metabolism. After 
these biologic changes, cognitive impairment can 
be detected, which culminates in clinical impair-
ment and eventually dementia. These findings 
suggest that the diagnosis of clinical dementia is 
made late in the course of the biologic cascade of 
autosomal dominant Alz hei mer’s disease.
The estimated year from expected symptom 
onset normalizes the stage of disease on the 
basis of the parental age of onset. Our findings 
suggest that once initiated, Alz hei mer’s disease 
processes are likely independent of absolute age 
but rather depend on the start of processes such 
as Aβ misfolding and other modulating factors. 
Furthermore, other findings suggest that amy-
loid deposition probably occurs years or decades 
before dementia symptoms are manifest in spo-
radic Alz hei mer’s disease.24 Previous cross-sec-
tional studies in sporadic Alz hei mer’s disease 
have suggested a series of changes that lead to 
clinical disease.2 Our results support the hy-
pothesis of a pathophysiological cascade and 
suggest the possibility of a common pathophys-
iology between autosomal dominant Alz hei-
mer’s disease and the much more common 
“sporadic” form.
A strength of this study is that it shows rela-
tive changes in Alz hei mer’s disease processes that 
occur over a period of four decades. However, 
interpretations of the results are not certain, 
because the current analyses are based on cross-
sectional data, which do not represent individual 
longitudinal changes. In addition, although 
many of our findings in autosomal dominant 
Alz hei mer’s disease are similar to findings in 
sporadic Alz hei mer’s disease, there were some 
differences. For example, trends for increased 
levels of Aβ42 in the CSF have not been reported 
in sporadic Alz hei mer’s disease or autosomal 
dominant Alz hei mer’s disease, although this 
trend was predicted in autosomal dominant Alz-
hei mer’s disease, because familial Alz hei mer’s 
disease mutations cause increased Aβ or Aβ42 
production.30 Furthermore, unlike sporadic Alz hei-
mer’s disease, autosomal dominant Alz hei mer’s 
disease typically presents with early and pro-
nounced PIB-PET signaling in the neostriatum.28 
Although the findings of this study were largely 
based on PSEN1 mutations, a comparison with 
PSEN2 and APP mutations (Table S2 in the Sup-
plementary Appendix) suggests no differences in 
results among the mutation gene types. Owing 
to the younger age of the cohort, the prevalence 
of confounders such as vascular risk factors was 
low (<15%) in this cohort and not significantly 
different between carriers and noncarriers. Al-
though the clinical and pathologic phenotypes of 
dominantly inherited Alz hei mer’s disease are 
similar to those of sporadic Alz hei mer’s disease, 
the generalizability of the nature and sequence 
of brain changes in autosomal dominant Alz hei-
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Figure 3. Aβ Deposition in Autosomal Dominant Alzheimer’s Disease Years 
before Expected Clinical Symptoms.
Panel A compares the fibrillar Aβ deposition, as measured by PET with the 
use of Pittsburgh compound B (PIB), of the average of autosomal dominant 
Alzheimer’s disease mutation carriers and noncarriers 20 years before the 
estimated time of onset of symptoms. There was significant Aβ deposition 
in the caudate and cortex in mutation carriers more than 10 years before 
expected symptom onset, as compared with noncarriers (Panel B). Panel C 
shows additional Aβ deposition throughout the cortex and neostriatum at 
the estimated time of symptom onset. An increased SUVR indicates increased 
binding of PIB to fibrillar amyloid. The scale ranges from low SUVR values 
(bluer colors), indicating low amounts of amyloid, to high SUVR values 
(redder colors), indicating high amounts of amyloid.
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mer’s disease remains to be determined for spo-
radic Alz hei mer’s disease.
The definition of the timing and magnitude 
of pathophysiological changes associated with 
Alz hei mer’s disease has implications for the de-
velopment and implementation of diagnostic and 
predictive tests and the design of prevention tri-
als.31 For example, our data suggest that amyloid 
deposition will develop and be detectable in all 
persons with a mutation while still asymptomat-
ic, whereas no noncarriers had positive scans for 
amyloid deposition. If autosomal dominant Alz-
hei mer’s disease is similar to late-onset Alz-
heimer’s disease, this finding suggests that 
Alz hei mer’s dementia will eventually develop in 
persons with positive scans for amyloid deposi-
tion. These findings suggest that the targeting of 
Aβ earlier in the course of the disease may pro-
vide better clinical outcomes than the treatment 
of mild to moderate dementia after substantial 
neuronal and synaptic loss has occurred.32
In summary, our findings indicate that the 
Alz hei mer’s disease process begins more than 
20 years before the clinical onset of dementia. 
Treatment and prevention trials can incorporate 
these pathophysiological changes to gauge the 
likelihood of future clinical success. Secondary 
prevention trials that are designed to prevent or 
delay cognitive and clinical impairment may ul-
timately test the amyloid hypothesis, just as the 
cholesterol hypothesis of heart disease was tested 
three decades ago.33
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